Skip to content

EV / EBITDA at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
30.3×
Royalty Pharma logo
Royalty PharmaRPRX
13.9×+1.7×
Theravance Biopharma logo
Theravance BiopharmaTBPH
199.8×
Innoviva, Inc. logo
Innoviva, Inc.INVA
7.5×+1.4×
Zymeworks logo
ZymeworksZYME
2.2×
ALN
Alnylam PharmaceuticalsALNY
52.6×

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

Based on the most recent quarter.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's EV / EBITDA?
XOMA Corporation (XOMA) reported EV / EBITDA of 49.8× in Q1 2026.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.